Humanigen Inc. (HGEN) Announces NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

ACTIV-5/BET-B trial amended in the context of Humanigens positive Phase 3 lenzilumab LIVE-AIR study Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L Study modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA) Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company developing a first-in-class GM-CSF... More